Please upgrade your browser.
Ono Pharma, Bristol-Myers & Kyowa Hakko Kirin enter pact to condutct phase 1 combo study with Opdivo & mogamulizumab in advanced solid tumors
Ono Pharmaceutical Co.,Ltd., Bristol-Myers Squibb Company and Kyowa Hakko Kirin Co., Ltd. have entered into a clinical trial collaboration agreement to conduct a phase 1 combination study with Opdivo (nivolumab), a PD-1 immune checkpoint inhibitor, and mogamulizumab, an anti-CCR4 antibody.
Research Led By NYU Langone Medical Center Shows Greater Experience Utilizing Robotic Surgery Leads to Better Use for Partial Nephrectomies
Being an extrovert can boost your immune system, but conscientiousness and being open can...
A drug approved to treat kidney cancer actually targeted that gene. Within two weeks of taking it, Wartman’s cancer was gone.
Once this is done, demand for these tests is expected to increase.
“Kidney disease and blindness, multiple digits, shortened bones or extremities, obesity—all of these things, it turns out, are due to defects in cilia,” he says.
“I just feel really grateful to God, or the universe, or whatever you want to call it,” Cohen said.
The Houston Police Department has made sure that a six-year-old girl fighting cancer has been able to live out one of her biggest dreams
End-of-life-care expert Timothy Quill carries out a discussion with neurosurgeon Paul Kalanithi who was diagnosed in 2013 with advanced-stage lung cancer.
Treatment with an immune checkpoint inhibitor led to consistent responses across multiple types of cancer...
|Powered by NeonCRM|